A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis | BMJ Open Gastroenterology

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

XML

Inflammatory bowel disease

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Online download statistics by month:

Online download statistics by month: August 2021 to March 2024

	Abstract	Full	Pdf
Aug 2021	637	631	203
Sep 2021	266	264	98
Oct 2021	274	268	52
Nov 2021	214	208	67
Dec 2021	212	215	81
Jan 2022	245	250	74
Feb 2022	205	201	70
Mar 2022	225	230	77
Apr 2022	191	184	58
May 2022	187	183	54
Jun 2022	168	168	27
Jul 2022	134	131	49
Aug 2022	130	129	58
Sep 2022	124	120	54
Oct 2022	128	124	37
Nov 2022	117	112	56
Dec 2022	85	85	22
Jan 2023	97	96	35
Feb 2023	175	182	63
Mar 2023	146	144	40
Apr 2023	124	124	40
May 2023	141	140	39
Jun 2023	133	136	31
Jul 2023	204	201	50
Aug 2023	166	170	38
Sep 2023	164	161	43
Oct 2023	150	146	39
Nov 2023	168	171	62
Dec 2023	117	101	42
Jan 2024	95	81	36
Feb 2024	152	154	52
Mar 2024	191	184	67
Total	5765	5694	1814